Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

被引：0
|
作者：
Zhengwu Sun
Xiaoyan Lan
Shizhao Xu
Shen Li
Yalin Xi
机构：
[1] Dalian Municipal Central Hospital,Department of Clinical Pharmacy
[2] Dalian Municipal Central Hospital,Department of Neurology
来源：
BMC Cancer | / 20卷
关键词：
Bevacizumab; Chemotherapy; HER2-negative metastatic breast cancer; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
    Wilson, Florence R.
    Varu, Abhishek
    Mitra, Debanjali
    Cameron, Chris
    Iyer, Shrividya
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 167 - 177
  • [22] Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer
    Refaat, Tamer
    Choi, Mehee
    Gaber, Germaine
    Kiel, Krystyna
    Mehta, Minesh
    Gradishar, William
    Small, William, Jr.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (05): : 480 - 485
  • [23] EVOLUTION OF CHEMOTHERAPY OPTIONS IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Verma, S.
    Zielinski, C.
    Martin, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 98 - 99
  • [24] Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials
    Li, Jun
    Yao, Yunfeng
    Jing, Juehua
    [J]. TUMOR BIOLOGY, 2014, 35 (07) : 6183 - 6183
  • [25] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
    Fabi, A.
    Russillo, M.
    Metro, G.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Giannarelli, D.
    Cognetti, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis
    Chen, Ruiliang
    Yu, Yushuai
    Zhang, Jie
    Song, Chuangui
    Wang, Chuan
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (07) : 599 - 611
  • [27] A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer
    Ge, Long
    Tang, Yan
    Zhang, Qiu-Ning
    Tian, Jin-Hui
    Wang, Xiao-Hu
    Pieper, Dawid
    Pan, Bei
    Li, Lun
    Ling, Juan
    Bing, Zhi-Tong
    Yang, Ke-Hu
    [J]. ONCOTARGET, 2017, 8 (35) : 59539 - 59551
  • [28] A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer
    Wang, T. S.
    Lei, W.
    Cui, W.
    Wen, P.
    Guo, H. F.
    Ding, S. G.
    Yang, Y. P.
    Xu, Y. Q.
    Lv, S. W.
    Zhu, Y. L.
    [J]. INDIAN JOURNAL OF CANCER, 2014, 51 (07) : 95 - 98
  • [29] Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer
    Wu, Ming
    Gong, Jianming
    Yu, Wei
    Geng, Jinhong
    Zeng, Linwen
    Kong, Xiangdong
    [J]. JOURNAL OF BUON, 2020, 25 (04): : 1814 - 1820
  • [30] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    [J]. TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
12345